The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
The dual SYK/JAK inhibitor cerdulatinib demonstrates rapid tumor responses in a phase 2 study in patients with relapsed/refractory B- and T-cell non-Hodgkin lymphoma (NHL).
 
Paul A. Hamlin
Honoraria - Portola Pharmaceuticals
Consulting or Advisory Role - Portola Pharmaceuticals
Travel, Accommodations, Expenses - Portola Pharmaceuticals
 
Bruce D. Cheson
Consulting or Advisory Role - Abbvie; Acerta Pharma; Bayer; Morphosys; Pharmacyclics/Janssen; Roche/Genentech; Sunesis Pharmaceuticals; TG Therapeutics
Research Funding - Abbvie (Inst); Acerta Pharma (Inst); Gilead Sciences (Inst); Roche/Genentech (Inst); TG Therapeutics (Inst)
 
Charles Michael Farber
No Relationships to Disclose
 
Tatyana Feldman
Honoraria - Abbvie; Bayer; Bristol-Myers Squibb; Kite, a Gilead company; Pharmacyclics/Janssen; Seagen
Consulting or Advisory Role - Bayer; Bristol-Myers Squibb; Seagen
Speakers' Bureau - Abbvie; Kite, a Gilead company; Pharmacyclics; Seagen
Research Funding - Amgen (Inst); Bristol-Myers Squibb (Inst); Eisai (Inst); Kyowa Hakko Kirin (Inst); Portola Pharmaceuticals (Inst); Seagen (Inst); Viracta Therapeutics (Inst)
Travel, Accommodations, Expenses - Abbvie; Kite, a Gilead company; Pharmacyclics; Seagen
 
Timothy S Fenske
No Relationships to Disclose
 
Brian T. Hess
No Relationships to Disclose
 
James L. Khatcheressian
No Relationships to Disclose
 
Carole Brennan Miller
No Relationships to Disclose
 
Javier Munoz
Consulting or Advisory Role - Alexion Pharmaceuticals; Bayer; Bristol-Myers Squibb; Gilead Sciences; Janssen; Kite, a Gilead company; Kyowa Hakko Kirin; Pfizer; Pharmacyclics; Seagen
Speakers' Bureau - Kite, a Gilead company
 
Manish R. Patel
Speakers' Bureau - Celgene; Exelixis; Genentech/Roche; Taiho Pharmaceutical
 
Sonali M. Smith
Consulting or Advisory Role - Abbvie/Genentech; Amgen; AstraZeneca; Celgene; Forty Seven; Genmab; Gilead Sciences; Juno Therapeutics; Kite, a Gilead company; NanoString Technologies; Pharmacyclics; Portola Pharmaceuticals; Roche; TG Therapeutics
 
Stephen Douglas Smith
No Relationships to Disclose
 
Don A. Stevens
No Relationships to Disclose
 
Jing Christine Ye
No Relationships to Disclose
 
Andrew Steele
Employment - Portola Pharmaceuticals
 
Anjali Pandey
Employment - Portola Pharmaceuticals
Stock and Other Ownership Interests - Portola Pharmaceuticals
 
Matt Birrell
Employment - Portola Pharmaceuticals
Stock and Other Ownership Interests - Portola Pharmaceuticals
 
Janet Leeds
Employment - Portola Pharmaceuticals
Stock and Other Ownership Interests - Portola Pharmaceuticals
 
Greg Coffey
Employment - Portola Pharmaceuticals
Stock and Other Ownership Interests - Portola Pharmaceuticals
 
John T Curnutte
Employment - Portola Pharmaceuticals
Stock and Other Ownership Interests - Portola Pharmaceuticals